Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS.
Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29.
Spatial multi-omic map of human myocardial infarction.
Kuppe C, Ramirez Flores RO, Li Z, Hayat S, Levinson RT, Liao X, Hannani MT, Tanevski J, Wünnemann F, Nagai JS, Halder M, Schumacher D, Menzel S, Schäfer G, Hoeft K, Cheng M, Ziegler S, Zhang X, Peisker F, Kaesler N, Saritas T, Xu Y, Kassner A, Gummert J, Morshuis M, Amrute J, Veltrop RJA, Boor P, Klingel K, Van Laake LW, Vink A, Hoogenboezem RM, Bindels EMJ, Schurgers L, Sattler S, Schapiro D, Schneider RK, Lavine K, Milting H, Costa IG, Saez-Rodriguez J, Kramann R.
Nature. 2022 Aug;608(7924):766-777. doi: 10.1038/s41586-022-05060-x. Epub 2022 Aug 10.
CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus.
Chen C, Lin LY, Chen JW, Chang TT.
Cardiovasc Diabetol. 2023 Jul 7;22(1):172. doi: 10.1186/s12933-023-01900-w.
Transcriptome wide changes in long noncoding RNAs in diabetic ischemic heart disease.
Rai AK, Muthukumaran NS, Nisini N, Lee T, Kyriazis ID, de Lucia C, Piedepalumbo M, Roy R, Uchida S, Drosatos K, Bisserier M, Katare R, Goukassian D, Kishore R, Garikipati VNS.
Cardiovasc Diabetol. 2024 Oct 17;23(1):365. doi: 10.1186/s12933-024-02441-6.
Calciphylaxis, beware the ophthalmic mimic: A case series.
Guymer C, Jahan S, Bahrami B, Sia D, Tan BQ, McDonald S, Simon S.
Clin Nephrol Case Stud. 2023 Dec 12;11:136-146. doi: 10.5414/CNCS111088. eCollection 2023.
Dietary capsaicin attenuates cardiac injury after myocardial infarction in type 2 diabetic mice by inhibiting ferroptosis through activation of TRPV1 and Nrf2/HMOX1 pathway.
Yang C, Guo W, He R, Meng X, Fu J, Lu Y.
Int Immunopharmacol. 2024 Oct 25;140:112852. doi: 10.1016/j.intimp.2024.112852. Epub 2024 Aug 5.
Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes.
Kufazvinei TTJ, Chai J, Boden KA, Channon KM, Choudhury RP.
Cardiovasc Res. 2024 Sep 21;120(11):1241-1252. doi: 10.1093/cvr/cvae142.
In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank.
Boonpor J, Pell JP, Ho FK, Celis-Morales C, Gray SR.
Diabetes Obes Metab. 2024 Feb;26(2):524-531. doi: 10.1111/dom.15338. Epub 2023 Oct 26.
Diabetic muscle infarction.
Mathew A, Reddy IS, Archibald C.
Emerg Med J. 2007 Jul;24(7):513-4. doi: 10.1136/emj.2006.040071.
Diabetic muscle infarction in end-stage renal disease: A scoping review on epidemiology, diagnosis and treatment.
Yong TY, Khow KSF.
World J Nephrol. 2018 Mar 6;7(2):58-64. doi: 10.5527/wjn.v7.i2.58.
